MONTVALE, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- As producers of choline chloride in the EU, Eastman and Balchem welcome the European Union's decision published on December 19, 2025 to adopt anti-dumping duties between 90.0 and 115.9% on choline chloride imports from the People's Republic of China.

David B Fischer directly sold 8,000 shares for a total of ~$1,231,748 on Dec. 3, 2025, at a weighted average price of around $154 per share. This transaction reduced his direct holdings by 50%, leaving him with 7,989 shares.

MONTVALE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at Baird's 55th Annual Global Industrial Conference on November 12, 2025.

I raise my rating for Balchem from "Hold" to "Buy," following my assessment of its performance and prospects. BCPC's 3Q2025 financials exceeded expectations, thanks to the strong showing from its Human Nutrition and Specialty Products segments. I'm anticipating that Balchem can realize growth acceleration in the mid-term by capitalizing on emerging food trends, a new production plant, and promising regulatory developments.

Balchem Corporation (NASDAQ:BCPC ) Q3 2025 Earnings Call October 21, 2025 11:00 AM EDT Company Participants Carl Bengtsson - Executive VP, CFO, Treasurer and GM of Animal Nutrition & Health Theodore Harris - CEO, President & Chairman Conference Call Participants Bob Labick - CJS Securities, Inc. Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Daniel Harriman - Sidoti & Company, LLC Presentation Operator Thank you for standing by.

Balchem (BCPC) came out with quarterly earnings of $1.35 per share, missing the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.03 per share a year ago.

Balchem reported record third-quarter sales. The company is growing sales while also supporting new growth initiatives.

Blachem (BCPC) came out with quarterly earnings of $1.35 per share, missing the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.03 per share a year ago.

Blachem (BCPC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MONTVALE, N. J.--(BUSINESS WIRE)--Balchem, a global manufacturer of specialty ingredients for human nutrition, has launched its first direct-to-consumer initiative.